PT - JOURNAL ARTICLE AU - Vilches, Thomas N. AU - Zhang, Kevin AU - Van Exan, Robert AU - Langley, Joanne M. AU - Moghadas, Seyed M. TI - Projecting the impact of a two-dose COVID-19 vaccination campaign in Ontario, Canada AID - 10.1101/2020.12.10.20246827 DP - 2020 Jan 01 TA - medRxiv PG - 2020.12.10.20246827 4099 - http://medrxiv.org/content/early/2020/12/11/2020.12.10.20246827.short 4100 - http://medrxiv.org/content/early/2020/12/11/2020.12.10.20246827.full AB - Background Results of phase III vaccine clinical trials against COVID-19, although encouraging and well above initial expectations, have only reported on efficacy against disease and its severity. We evaluated the impact of vaccination on COVID-19 outbreak and disease outcomes in Ontario, Canada.Methods We used an agent-based transmission model and parameterized it with COVID-19 characteristics, demographics of Ontario, and age-specific clinical outcomes derived from outbreak data. We implemented a two-dose vaccination program, prioritizing healthcare workers and high-risk individuals, with 40% vaccine coverage and vaccine efficacy of 95% against disease. Vaccines were distributed at a rate of 30 doses per day per 10,000 population with a 6-day schedule per week. We projected the impact of vaccination on attack rates, hospitalizations, and deaths. For scenario analyses, we varied the vaccine efficacy against infection, under the assumption of 5% pre-existing population immunity.Results With no protection against infection, a two-dose vaccination campaign with a time interval of 21 days between doses reduced attack rate, hospitalizations, and deaths by 44.6% (95% CrI: 34.5% - 54.3%), 63.4% (95% CrI: 56.1% - 69.9%), and 70.0% (95% CrI: 62.6% - 75.8%), respectively. These reductions were improved with increased vaccine efficacy against infection, with similar estimated ranges in the corresponding scenarios with a 28-day time interval between vaccine doses.Conclusions Vaccination can substantially mitigate ongoing COVID-19 outbreaks, even when vaccines offer limited protection against infection. This impact is founded upon a relatively strong vaccine efficacy against disease and severe outcomes.Competing Interest StatementJML's institution has received funding for research studies from Sanofi Pasteur, GlaxoSmithKline, Merck, Janssen and Pfizer. JML holds the CIHR-GSK Chair in Paediatric Vaccinology. Other authors declare no competing interests.Funding StatementSMM gratefully acknowledges the Canadian Institutes of Health Research OV4-170643, COVID-19 Rapid Research; and Natural Sciences and Engineering Research Council of Canada. TNV acknowledges the support of the São Paulo Research Foundation, grant #2018/24811-1.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was not required as all data is publicly available.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe model was coded in Julia language and is available at: https://github.com/thomasvilches/vac_covid_ontario. https://github.com/thomasvilches/vac_covid_ontario